LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 116 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $582,046 | +74046.0% | 583,622 | +10.0% | 0.00% | 0.0% |
| Q1 2024 | $785 | +378.7% | 530,600 | +253.7% | 0.00% | – |
| Q4 2023 | $164 | +134.3% | 150,000 | +151.3% | 0.00% | – |
| Q3 2023 | $70 | -11.4% | 59,700 | +6.8% | 0.00% | – |
| Q2 2023 | $79 | -99.8% | 55,900 | +143.0% | 0.00% | – |
| Q4 2020 | $40,000 | -90.7% | 23,000 | -95.0% | 0.00% | – |
| Q3 2020 | $432,000 | +0.9% | 460,806 | -6.3% | 0.00% | – |
| Q2 2020 | $428,000 | +92.8% | 491,700 | +83.2% | 0.00% | – |
| Q1 2020 | $222,000 | – | 268,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $52,403,228 | 3.69% |
| Raffles Associates | 1,536,946 | $2,305,419 | 3.14% |
| Defender Capital, LLC. | 5,136,085 | $7,704,128 | 2.69% |
| Prescott General Partners LLC | 1,851,851 | $2,777,777 | 0.22% |
| DAFNA Capital Management LLC | 140,000 | $210,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $67,500 | 0.05% |
| CTC Capital Management, LLC | 14,100 | $21,150 | 0.04% |
| Diametric Capital, LP | 50,875 | $76,313 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $1,172,649 | 0.03% |
| One68 Global Capital, LLC | 13,377 | $20,066 | 0.03% |